文献速递胸部CT

基于治疗前CT的加权影像组学联合临床特征预测晚期肺癌免疫治疗持久临床获益

A pre-treatment CT-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer.
PubMed 文献 · Eur Radiol · 2022-12-14

本研究为单中心回顾性研究,开发并交叉验证基于治疗前CT的影像组学模型,用于预测不可手术肺癌患者免疫治疗的PFS。研究纳入185例开发集和48例测试集,采用注意力多实例学习对多肺内病灶影像组学特征加权,联合5项临床特征后逻辑回归模型在训练、验证和测试集的AUC分别为0.91、0.86和0.86,Kaplan-Meier分析显示预测DCB与NDCB组PFS分层明显(HR=2.40-2.95,p<0.05)。

要点

  • 多肺内病灶加权影像组学特征优于最大病灶或平均求和策略。
  • 联合5项临床特征可显著提升影像组学模型预测效能。
  • 预测DCB与NDCB组间PFS分层显著(HR=2.40-2.95)。

局限性

  • 单中心回顾性研究,样本量有限,需外部多中心验证。
  • 测试集样本量较小(48例),模型泛化能力需进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To develop a pre-treatment CT-based predictive model to anticipate inoperable lung cancer patients' progression-free survival (PFS) to immunotherapy.

METHODS: This single-center retrospective study developed and cross-validated a radiomic model in 185 patients and tested it in 48 patients. The binary endpoint is the durable clinical benefit (DCB, PFS ≥ 6 months) and non-DCB (NDCB, PFS < 6 months). Radiomic features were extracted from multiple intrapulmonary lesions and weighted by an attention-based multiple-instance learning model. Aggregated features were then selected through L2-regularized ridge regression. Five machine-learning classifiers were conducted to build predictive models using radiomic and clinical features alone and then together. Lastly, the predictive value of the model with the best performance was validated by Kaplan-Meier survival analysis.

RESULTS: The predictive models based on the weighted radiomic approach showed superior performance across all classifiers (AUCs: 0.75-0.82) compared with the largest lesion approach (AUCs: 0.70-0.78) and the average sum approach (AUCs: 0.64-0.80). Among them, the logistic regression model yielded the most balanced performance (AUC = 0.87 [95%CI 0.84-0.89], 0.75 [0.68-0.82], 0.80 [0.68-0.92] in the training, validation, and test cohort respectively). The addition of five clinical characteristics significantly enhanced the performance of radiomic-only model (train: AUC 0.91 [0.89-0.93], p = .042; validation: AUC 0.86 [0.80-0.91], p = .011; test: AUC 0.86 [0.76-0.96], p = .026). Kaplan-Meier analysis of the radiomic-based predictive models showed a clear stratification between classifier-predicted DCB versus NDCB for PFS (HR = 2.40-2.95, p < 0.05).

CONCLUSIONS: The adoption of weighted radiomic features from multiple intrapulmonary lesions has the potential to predict long-term PFS benefits for patients who are candidates for PD-1/PD-L1 immunotherapies.

KEY POINTS: • Weighted radiomic-based model derived from multiple intrapulmonary lesions on pre-treatment CT images has the potential to predict durable clinical benefits of immunotherapy in lung cancer. • Early line immunotherapy is associated with longer progression-free survival in advanced lung cancer.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Zhu, Chen, Hu, et al. A pre-treatment CT-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer. Eur Radiol. 2022. PMID: 36515714. doi:10.1007/s00330-022-09337-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。